Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about ...

Q1 2025 Earnings Call Transcript May 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.52, expectations ...

Moderna (NASDAQ:MRNA) accelerates cost cuts, trimming 2026 GAAP operating expenses by up to $500 million as COVID-19 vaccine ...

Lavina Talukdar; Senior Vice President & Head of Investor Relations; Moderna Inc. Stephane Bancel; Chief Executive Officer, Director; Moderna Inc. James Mock; Chief ...

If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

The US Department of Health and Human Services said Thursday that it aims to accomplish within four years a scientific feat ...

The company reported first-quarter revenue of $108 million, down from $167 million in the corresponding period of 2024, and ...

Product sales were down 49% year over year to $86 million due to lower Spikevax sales. The company recorded $84 million from Spikevax sales in the quarter compared with $167 million in the year-ago ...

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

Blood from a snake enthusiast who's been bitten hundreds of times aided the search for a universal snakebite treatment ...